N,N-DMT (Tryptamine · Endogenous Psychedelic · Research Reference)
| Compound | N,N-Dimethyltryptamine (DMT; Nigerine; Desoxybufotenin) |
| Class | Alkaloid — Tryptamine (Indole) |
| CAS | 61-50-7 |
| Molecular formula | C₁₂H₁₆N₂ |
| Primary sources | Mimosa tenuiflora (root bark), Psychotria viridis, Acacia confusa, numerous plant families |
| Plant part | Root bark, leaves, stem bark |
| Claim strength | Emerging |
| Key applications | Psychedelic research; endogenous neuromodulator; ayahuasca component; informational-only |
| Buy from Herbuno | Informational reference — see HerbIQ Compound Index → |
Name origin: N,N-Dimethyltryptamine (DMT) is named by its chemical structure — tryptamine with two N-methyl groups. The "nigerine" synonym reflects early isolation from Piptadenia nigra (now Anadenanthera colubrina). Traditional use: DMT-containing plant preparations have been used in Amazonian shamanic traditions for centuries — most notably in ayahuasca (a combination of Psychotria viridis leaves with Banisteriopsis caapi vine), and in snuff preparations (yopo, epena) from Anadenanthera and Virola species used by indigenous peoples of South America. Ayahuasca ceremonies involve structured ritual contexts supervised by experienced practitioners (ayahuasceros). Research trajectory: DMT is both a plant alkaloid and an endogenous mammalian compound — detected in human urine, blood, cerebrospinal fluid, and retina. The endogenous DMT hypothesis proposes roles in dreaming, near-death experience phenomenology, and baseline serotonergic tone, though the endogenous concentrations and functional significance remain contested. Modern clinical research (Imperial College London, Johns Hopkins, NYU) has investigated DMT and ayahuasca for treatment-resistant depression, PTSD, and addiction. Breakthrough therapy designation has been explored for psilocybin (a structurally related tryptamine); DMT research is at an earlier clinical stage. Safety and legal context: DMT is a Schedule I controlled substance in the US, Class A in the UK, and similarly controlled across most jurisdictions. It is not a supplement, food, or cosmetic ingredient.
Research Profile of N,N-DMT
Serotonergic mechanism: DMT is a potent agonist at 5-HT2A and 5-HT2C receptors — the same receptor targets as psilocybin and LSD. 5-HT2A agonism in cortical pyramidal neurons is the primary mechanism of psychedelic effects. DMT also acts at sigma-1 receptors (which may mediate neuroprotective effects at sub-psychedelic concentrations), trace amine-associated receptor 1 (TAAR1), and multiple serotonin receptor subtypes. Claim strength: Moderate (mechanistic).
Clinical psychedelic research: Phase I/II trials of intravenous DMT (as the fumarate salt) have been conducted at Imperial College London — demonstrating safety, dose-dependent psychedelic effects, and feasibility of extended DMT infusion for therapeutic sessions. DMT's very short duration of action (15–30 minutes IV) makes it logistically distinct from psilocybin (4–6 hours) and potentially more adaptable for clinical delivery models. Claim strength: Emerging (early clinical).
Ayahuasca clinical evidence: Ayahuasca (DMT + beta-carboline MAOIs from B. caapi) has multiple small RCTs and open-label trials demonstrating antidepressant effects in treatment-resistant depression — most notably a Brazilian double-blind RCT (Palhano-Fontes 2019, Psychological Medicine) showing significant MADRS score reduction at day 7 versus placebo. Translating this to isolated DMT versus the ayahuasca combination is not straightforward. Claim strength: Moderate (ayahuasca combination).
Endogenous neurobiology: DMT has been detected at nanomolar concentrations in rat brain under normal conditions and at elevated concentrations following cardiac arrest — consistent with near-death experience phenomenology hypotheses. Human endogenous DMT physiology is under active investigation. Claim strength: Emerging.
This compound is documented for research and formulator education purposes. For commercially available botanical ingredients, explore the HerbIQ Compound Index →
Regulatory and Research Context
DMT is Schedule I (US DEA), Class A (UK), and similarly controlled internationally. Religious exemptions exist in some jurisdictions for ayahuasca use by established religious organisations (União do Vegetal, Santo Daime — US federal exemptions established by Supreme Court ruling 2006). Research use requires DEA Schedule I researcher registration and institutional DEA site licence.
No supplement, food, cosmetic, or nutraceutical application exists or is appropriate. Botanical raw materials containing DMT (Mimosa tenuiflora root bark, Psychotria viridis leaves) are legal to possess in some jurisdictions but are controlled in others — jurisdictional variation is significant.
The clinical research trajectory for DMT (and structurally related psilocybin) is among the most actively developing areas in psychiatry. Formulators and researchers should monitor regulatory developments closely — the psychedelic medicine regulatory landscape is evolving rapidly in the US, UK, Australia, and Canada.
This entry provides pharmacological and research context for the DMT tryptamine class. The HerbIQ index documents DMT as part of its complete tryptamine alkaloid series for formulator and researcher education.
Frequently Asked Questions — N,N-DMT
What is ayahuasca and how does DMT function within it?
Ayahuasca is a psychoactive brew combining Psychotria viridis (DMT-containing leaves) with Banisteriopsis caapi (containing beta-carboline harmala alkaloids — harmine, harmaline, tetrahydroharmine). Oral DMT is normally rapidly degraded by monoamine oxidase (MAO) in the gut and liver; the beta-carboline MAOIs in B. caapi inhibit MAO, allowing oral DMT to reach systemic circulation and cross the blood-brain barrier. Without the MAOI component, oral DMT is pharmacologically inactive.
Is DMT truly produced endogenously in humans?
Yes — DMT has been detected in human urine, blood, and CSF using sensitive analytical methods (GC-MS, LC-MS). The biosynthetic enzyme indolethylamine N-methyltransferase (INMT), which converts tryptamine to DMT via successive methylation, is expressed in human lung, thyroid, and adrenal tissue. Whether endogenous DMT serves physiological neuromodulatory functions at normal concentrations remains unresolved — it is a subject of active research rather than established pharmacology.
How does DMT compare to psilocybin as a psychedelic medicine candidate?
Psilocybin (prodrug to psilocin — a 4-hydroxy tryptamine) has a longer duration (4–6 hours), enabling structured therapeutic sessions without continuous infusion. DMT's very short IV duration (15–30 minutes) requires infusion for extended sessions but offers more precise pharmacokinetic control and potentially shorter treatment windows. Both act primarily via 5-HT2A agonism. Psilocybin is further advanced clinically (FDA Breakthrough Therapy for depression, multiple Phase IIb/III trials); DMT clinical research is at Phase I/IIa.
Which plants contain DMT at commercially significant concentrations?
Mimosa tenuiflora (jurema preta) root bark (0.57% DMT dry weight), Acacia confusa root bark (~1% DMT), Psychotria viridis leaves (0.1–0.6%), and Anadenanthera colubrina seeds (primarily bufotenin with some DMT) are the most commercially relevant DMT-containing plant materials. Most are legal to purchase as botanical specimens in the US and EU while remaining controlled as drug precursors in manufacturing contexts — jurisdictional legal status should be verified before any commercial transaction.
Related compounds: Bufotenin, 5-MeO-DMT, Harmine, Harmaline
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery